Cargando…
Immunotherapy for Prostate Cancer: Where We Are Headed
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has bec...
Autores principales: | Schepisi, Giuseppe, Farolfi, Alberto, Conteduca, Vincenza, Martignano, Filippo, De Lisi, Delia, Ravaglia, Giorgia, Rossi, Lorena, Menna, Cecilia, Bellia, Salvatore Roberto, Barone, Domenico, Gunelli, Roberta, De Giorgi, Ugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751230/ https://www.ncbi.nlm.nih.gov/pubmed/29206214 http://dx.doi.org/10.3390/ijms18122627 |
Ejemplares similares
-
Psychosocial Issues in Long-Term Survivors of Testicular Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019) -
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018) -
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021) -
Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019) -
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)